Avantax Advisory Services’s BioMarin Pharmaceuticals BMRN Stock Holding History

Avantax Advisory Services’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$388K	Buy	7,061 +614	+10%	+$36.2K	﹤0.01%	1736
2025 Q1	$456K	Buy	6,447 +497	+8%	+$33.4K	﹤0.01%	1563
2024 Q4	$391K	Buy	5,950 +1,630	+38%	+$109K	﹤0.01%	1610
2024 Q3	$304K	Sell	4,320 -88	-2%	-$7.36K	﹤0.01%	1738
2024 Q2	$363K	Buy	4,408 +997	+29%	+$83K	﹤0.01%	1572
2024 Q1	$298K	Buy	+3,411	New	+$305K	﹤0.01%	1296

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Avantax Advisory Services's BMRN Position: Q2 2025 in Review

Avantax Advisory Services increased its BioMarin Pharmaceuticals (BMRN) stake by 9.5% in Q2 2025, buying an estimated $36.2K and bringing the position to 7,061 shares worth $388K. The position accounts for ﹤0.01% of the portfolio, ranked #1736.

Avantax Advisory Services first reported a position in BMRN in Q1 2024 and has held it in 6 quarters since. The position peaked at $456K in Q1 2025. 582 funds tracked by Wall St. Rank hold BMRN as of Q2 2025.

Avantax Advisory Services held 7,061 shares of BioMarin Pharmaceuticals worth $388K as of Q2 2025.
Avantax Advisory Services bought 614 BioMarin Pharmaceuticals shares in Q2 2025, an estimated $36.2K.
BioMarin Pharmaceuticals made up ﹤0.01% of Avantax Advisory Services's portfolio in Q2 2025, its #1736 holding.
Avantax Advisory Services first reported a position in BioMarin Pharmaceuticals in Q1 2024 and has held it in 6 quarters since.
Avantax Advisory Services's BioMarin Pharmaceuticals position peaked at $456K in Q1 2025.
582 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2025.

Based on Avantax Advisory Services's 13F filing for Q2 2025, filed 8 Aug 2025.